Apolipoprotein H is increased in type 2 diabetic patients with microalbuminuria

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 10, Issue 6, 2000, Pages 311-314

  Cavallo Perin, P ^a,b   Gruden, G ^a   Giunti, S ^a   Arnaldi, L ^a   Cassader, M ^a   Gambino, R ^a   Pagano, G ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

Apo H; Microalbuminuria; Type 2 diabetes

Indexed keywords

ANTICOAGULANT AGENT; BETA2 GLYCOPROTEIN 1; GLYCOPROTEIN;

ALBUMINURIA; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; DIABETIC NEPHROPATHY; FEMALE; HUMAN; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR;

ALBUMINURIA; ANTICOAGULANTS; BETA 2-GLYCOPROTEIN I; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; GLYCOPROTEINS; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 0034570151     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Bruno G, Cavallo Perin P, Bargero G, Borra M, Calvi V, D'Errico N, Deambrogio P, Pagano G (1996) Prevalence and risk factors for micro-and macroalbuminuria in an Italian population-based cohort of NIDDM subjects. Diabetes Care 19: 43-47
2. Polz E, Kostner GM (1979) The binding of β2-glycoprotein-I to human serum lipoproteins. Distribution among density fractions. FEBS Lett. 102: 183-186
3. Gambino R, Ruiu G, Pagano G, Cassader M (1999) The binding of apolipoprotein H (β2-glycoprotein I) to lipoproteins. Prostaglandins 57: 351-359
4. Cassader M, Ruiu G, Gambino R, Veglia F, Pagano G (1997) Apolipoprotein H levels in diabetic subjects: correlation with cholesterol levels. Metabolism 46: 522-525
5. The Diabetes Control and Complications Trial Data Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986
6. Lam KS, Cheng IK, Janus ED, Pang RW (1995) Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 38: 604-609
7. World Health Organization (1985) Diabetes mellitus: report of a WHO study group. WHO Tech Report Series 727: 1-113
8. Friedewald WT, Levy RI, Frederickson DS (1972) Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18: 499-502
9. Gambino R, Ruiu G, Cassader M, Pagano G (1996) Apolipoprotein H: a two-step isolation method. J Lipid Res 37: 902-904
10. Brownlee M (1994) Glycation and diabetic complications. Diabetes 43: 836-841
11. Gambino R, Ruiu G, Pagano G, Cassader M (1999) Apolipoprotein H is not affected by in vitro glycation. J Protein Chem 18: 173-177
12. Ruiu G, Gambino R, Veglia F, Pagano G, Cassader M (1997) Influence of APOH protein polymorphism on apoH levels in normal and diabetic subjects. Clin Genet 52: 1-6
13. Niskanen L, Uusitupa M, Sarlund H, Siitonen O, Voutilainen E, Penttila I, Pyorala K (1990) Microalbuminuria predicts the development of serum lipoprotein abnormalities favouring atherogenesis in newly diagnosed type 2 (non-insulin-dependent) diabetic patients. Diabetologia 33: 237-243
14. Lee NS, Brewer HB Jr, Osborne JC Jr (1983) β2-glycoprotein-I. Molecular properties of an unusual apolipoprotein, apolipoprotein H. J Biol Chem 25: 4765-4770
15. Wahl P, Deppermann D, Hasslacher C (1982) Biochemistry of glomerular basement membrane of the normal and diabetic human. Kidney Int 21: 744-749